Answers are grounded in this paper and cite their sources.
Review introduces Sequence-Dominant Protein Therapeutics, validating their role in improving biologics efficiency.
The pharmaceutical industry’s substantial investment in structure-based drug design, catalyzed by advances in protein structure prediction including AlphaFold’s near-experimental accuracy, has yielded limited measurable improvements in biologics development productivity metrics, with clinical attrition rates, development timelines, and manufacturing failures remaining statistically unchanged from historical baselines despite widespread discussion of having “solved” protein folding. This review introduces and validates Sequence-Dominant Protein Therapeutics (SDPTs), a mechanistically defined class of biologics whose functional activity is determined primarily by amino acid sequence-encoded local chemical features rather than global conformational dynamics, operationally defined as proteins that function predominantly through direct stoichiometric binding without conformational signaling, exhibit near-linear dose-response relationships with Hill coefficients typically between 0.9 and 1.1 (recognized as a useful operational benchmark rather than a strict binary boundary, given that sequence dominance exists along a mechanistic continuum), maintain activity across structural variants with conserved binding epitopes, and demonstrate clinical equivalence in biosimilars despite structural variations, while explicitly excluding Fc-effector-dependent antibodies, geometry-critical bispecifics, and proteins requiring conformational switching like insulin analogs. Through systematic analysis of FDA- and EMA-approved biologics from 2015 to 2024 (assembled using pre-specified eligibility criteria detailed in Section 3.1, with explicit controls for survivorship and publication bias), examination of 127 biosimilar clinical equivalence studies, and structure-function relationships across therapeutic protein classes, our analysis indicates that SDPTs comprise approximately 73% of FDA-approved antibody therapeutics and 81% of enzyme replacement therapies with standardized trafficking, with sequence-informed functional assays suggesting greater than 90% concordance with clinical outcomes while structural variations show minimal correlation with therapeutic efficacy ( r 2 < 0.15, p > 0.05), and biosimilar studies revealing consistent clinical equivalence despite 15%–30% structural differences when sequence-encoded binding epitopes are preserved; these proportions should be interpreted as estimates subject to the limitations of approved-product data and the underreporting of failed programs. Recognition of sequence dominance enables evidence-efficient development while maintaining rigorous safety and efficacy standards, with proposed mechanism-based regulatory frameworks potentially reducing development time by 30%–40% and costs by $100–200 million per program based on scenario modeling incorporating explicit assumptions about adoption rates, phase-specific efficiencies, and market dynamics (detailed sensitivity analyses are presented in Section 7), though implementation requires coordinated changes in discovery approaches, regulatory pathways, and development strategies to realize the projected industry-wide benefits of $45–65 billion over the next decade while expanding global access to biological medicines through simplified development and local production capabilities.
No takes yet. Share an insight, caveat, or question.
Sarfaraz K. Niazi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: